What is the recommended Helicobacter pylori eradication regimen for a 10-year-old child weighing 44 kg, using amoxicillin, rifabutin, and a proton‑pump inhibitor?

Rifabutin Triple Therapy for H. pylori in a 10-Year-Old Child

For this 10-year-old child weighing 44 kg with H. pylori infection, use rifabutin 150 mg once daily, amoxicillin 1000 mg twice daily, and a standard-dose PPI twice daily for 10 days. This regimen is appropriate as a rescue therapy after prior treatment failures, though it should not be used as first-line therapy 1.

Dosing Specifics

Rifabutin

• Dose: 150 mg once daily for 10 days
• At 44 kg, this child can receive the adult dose of 150 mg daily (the lower of the two adult dosing options) 1
• The 300 mg daily dose is also used in adults, but 150 mg is reasonable for this weight and minimizes myelotoxicity risk

Amoxicillin

• Dose: 1000 mg (1 gram) twice daily for 10 days
• FDA labeling indicates pediatric dosing of 20-45 mg/kg/day divided every 8-12 hours 2
• At 44 kg, this translates to 880-1980 mg/day; 2000 mg/day (1 gram BID) falls within this range
• Adult dosing of 1 gram twice daily is appropriate for this weight 1, 2

Proton Pump Inhibitor

• Standard adult dose twice daily (e.g., omeprazole 20 mg BID, lansoprazole 30 mg BID, or pantoprazole 40 mg BID)
• Given 30 minutes before meals on an empty stomach 1
• At 44 kg, adult PPI dosing is appropriate

Clinical Context and Positioning

This rifabutin-based regimen should only be used as rescue therapy after multiple treatment failures, not as first-line treatment 1. The 2021 AGA guideline positions rifabutin triple therapy after failure of:

• Initial clarithromycin-based triple therapy
• Bismuth quadruple therapy (if used as second-line)

The rationale for using rifabutin without prior susceptibility testing is that rifabutin and amoxicillin resistance are rare (<15% for rifabutin), making empiric use reasonable in the rescue setting 1.

Important Caveats

Myelotoxicity Risk

• Monitor for reversible myelotoxicity including leukopenia and thrombocytopenia 3
• Consider baseline and follow-up complete blood counts, particularly if treatment extends beyond 10 days
• This is the primary safety concern with rifabutin use

Efficacy Considerations

• Meta-analysis data show modest eradication rates: 70.4% by intent-to-treat and 72.0% by per-protocol analysis 4
• The rifabutin regimen may not be superior to other rescue regimens 4
• However, it remains a viable option when other antibiotics have failed or resistance is suspected

Alternative Considerations

If this is truly first-line therapy (not rescue), do not use rifabutin. Instead, use:

• Amoxicillin 1 gram BID + clarithromycin 500 mg BID + PPI BID for 14 days (if clarithromycin resistance is <15% locally) 2
• Bismuth quadruple therapy for 14 days (if available and metronidazole resistance is high) 5

Duration

• 10 days is the standard duration for rifabutin triple therapy 1
• This is shorter than the 14-day duration typically used for other triple therapies
• The shorter duration may improve adherence while maintaining efficacy

Practical Implementation

1. Confirm this is rescue therapy (not first-line) and that prior regimens have failed with documented adherence
2. Prescribe:
   • Rifabutin 150 mg capsule: 1 capsule once daily × 10 days
   • Amoxicillin 500 mg capsule: 2 capsules twice daily × 10 days
   • PPI (e.g., omeprazole 20 mg): 1 capsule twice daily × 10 days
3. Instruct: Take PPI 30 minutes before breakfast and dinner; take amoxicillin with meals; take rifabutin once daily
4. Monitor: Consider CBC if prolonged therapy or symptoms of myelosuppression develop
5. Confirm eradication: Urea breath test or stool antigen test ≥4 weeks after completing therapy 6

Recurrence Monitoring

• 13.7% recurrence rate has been documented in pediatric patients, predominantly in children <10 years 6
• Follow-up testing at 6 and 12 months post-eradication is prudent in this age group 6